← Back to Search

Monoclonal Antibodies

Zr89 Imaging for Melanoma

Q: Is this research study still recruiting new participants?

<p>This study is not actively recruiting patients at this time, according to the clinicaltrials.gov website. The trial was first posted on March 8th, 2022 and was last updated on May 31st, 2022. Although this specific study is not looking for candidates right now, there are 789 other trials that are currently open and accepting participants.</p>

Phase < 1

Waitlist Available

Research Sponsored by Abramson Cancer Center of the University of Pennsylvania

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

At least one site of measurable disease (per RECIST 1.1) that is seen on CT, MRI, or FDG PET/CT

History of histologically confirmed melanoma as assessed per medical record review

Timeline

Screening 3 weeks

Treatment Varies

Follow Up until the end of the study, usually about 3 years

Awards & highlights

Study Summary

This trial is testing a new way to image melanoma in order to better assess an early response to therapy. Patients with melanoma who are eligible for the trial and have at least one site of measurable disease will be potentially eligible.

Who is the study for?

Adults with advanced melanoma who are eligible for the LIMIT Melanoma Trial, have at least one measurable disease site, and proper organ function. Pregnant or breastfeeding women, those unable to tolerate imaging procedures, with serious medical conditions, ineligible for the LIMIT trial or with splenic disorders are excluded.Check my eligibility

What is being tested?

The study tests Zirconium Zr 89 Crefmirlimab Berdoxa PET/CT as a marker for early response in melanoma patients receiving immunotherapy and hydroxychloroquine. It aims to correlate imaging results with progression-free survival (PFS) and overall survival (OS).See study design

What are the potential side effects?

While specific side effects of Zirconium Zr 89 Crefmirlimab Berdoxa aren't listed here, PET/CT scans may cause discomfort or reactions related to tracer injection; consult your doctor about potential risks.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have at least one tumor that can be measured on scans.

Select...

My melanoma diagnosis has been confirmed by a tissue examination.

Select...

My blood, liver, and kidney functions meet the trial's required levels.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ until the end of the study, usually about 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~until the end of the study, usually about 3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and until the end of the study, usually about 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in uptake post therapy

Zirconium Zr 89 Crefmirlimab Berdoxa uptake

Secondary outcome measures

CD8+ TIL density in tumor

Post therapy outcomes

Trial Design

1Treatment groups

Experimental Treatment

Group I: PET imagingExperimental Treatment1 Intervention

This is a single institution, prospective cohort study of 89Zr-Df-IAB22M2C PET/CT as an early measure of response in patients with melanoma.

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Abramson Cancer Center of the University of PennsylvaniaLead Sponsor

359 Previous Clinical Trials

105,075 Total Patients Enrolled

Abramson Cancer Center at Penn MedicineLead Sponsor

387 Previous Clinical Trials

145,675 Total Patients Enrolled

ImaginAb, Inc.Industry Sponsor

12 Previous Clinical Trials

280 Total Patients Enrolled

Media Library

Crefmirlimab Berdoxa (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05279027 — Phase < 1

Skin Cancer Research Study Groups: PET imaging

Skin Cancer Clinical Trial 2023: Crefmirlimab Berdoxa Highlights & Side Effects. Trial Name: NCT05279027 — Phase < 1

Crefmirlimab Berdoxa (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05279027 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research study still recruiting new participants?

"This study is not actively recruiting patients at this time, according to the clinicaltrials.gov website. The trial was first posted on March 8th, 2022 and was last updated on May 31st, 2022. Although this specific study is not looking for candidates right now, there are 789 other trials that are currently open and accepting participants."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Zr89 + PET Companion Trial

2022. "Zr89 + PET Companion Trial". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05279027.